What is Vitrakvi (larotrectinib)?
Last reviewed: October 2019
- FDA Approves Vitrakvi (Larotrectinib) for Tumors with Certain Genetic Change. American Cancer Society. https://www.cancer.org/latest-news/fda-approves-vitrakvi-larotrectinib-for-tumors-with-certain-genetic-change.html Published November 28, 2018. Accessed October 23, 2019.
- Vitrakvi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Published November 2018. Accessed October 23, 2019.
- FDA Approves an Oncology Drug That Targets a Key Genetic Driver of Cancer, Rather Than a Specific Tumor. US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor Published November 26, 2018. Accessed October 23, 2019.